The global bleeding disorder testing market is poised for remarkable growth over the next decade. Valued at USD 95 billion in 2023, the market is projected to expand at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2033, ultimately reaching a total of USD 190 billion by 2033.
The rising prevalence of various bleeding disorders, including Von Willebrand disease, haemophilia A, haemophilia B, and other related conditions, is driving the demand for enhanced testing solutions. As awareness increases and diagnostic technologies improve, the need for accurate, timely testing is becoming more critical, fueling market growth.
The growth of the bleeding disorder testing market is largely attributed to the increasing prevalence of various bleeding disorders, including Von Willebrand disease, haemophilia A, haemophilia B, and other related conditions. As the awareness and diagnosis of these disorders improve, there is a growing demand for comprehensive testing solutions to manage and treat these conditions effectively.
This upward trend reflects advancements in diagnostic technologies and the heightened focus on early detection and accurate diagnosis of bleeding disorders. The market’s expansion underscores the critical role of diagnostic testing in improving patient outcomes and advancing treatment options.
In the affected body location, a clump of platelets and a specific type of blood cell forms. This clot keeps infections out of the bloodstream and prevents blood from draining from the injured area. Testing for bleeding disorders can help determine whether specific clotting factors are present and how long it takes for blood to clot.
The test measures the time it takes for the arteries to contract and platelets in the blood to close the opening. According to the National Haemophilia Foundation, Von Willebrand disease is the most common bleeding disorder, affecting around one in every 100 people, or up to 1% of the US population.
Bleeding Disorder Testing Market Key Takeaways:
- According to FMI, the Global Bleeding Disorder Testing market will grow at a 7.2% CAGR by 2033.
- The global bleeding disorder testing industry is predicted to be worth $ 95 billion.
- The global bleeding disorder testing industry is anticipated to be worth US$ 190 billion.
- North America is expected to be the most profitable market for Bleeding Disorder Testing growth.
- According to Future Market Insights, Asia Pacific is predicted to develop at a CAGR of 6.5% from 2023 to 2033.
- Europe is predicted to increase at a CAGR of 6.9% between 2023 and 2033.
- In the forecast period 2023 to 2033, the diagnostic centers category is estimated to hold the greatest market share for Bleeding Disorder Testing.
“The North American market is expected to expand significantly throughout the projected period. The increase can be attributed to the increased availability of testing devices and the rising number of regulatory approvals,” says an analyst at FMI
A Old Full Report Analysis Click Here
Bleeding Disorder Testing Market Growth:
Increasing Blood Disorder Prevalence to Improve Maintenance and Performance
Chronic illness includes blood issues. They are also hazardous since they circulate in the blood. The prevalence of conditions such as liver disease, anaemia, and other blood coagulation concerns has increased, as has the demand for bleeding disorders testing. These inherited diseases resulted in a profitable market expansion.
Government Investments in Healthcare Interoperability Have an Impact on the Market
The increasing funding provided by the federal government to encourage the use of these solutions has an additional impact on the sector. Furthermore, rising healthcare spending, advancements in healthcare infrastructure, and rising need for long-term care delivery all benefit the bleeding disorders testing sector, promoting market expansion.
Bleeding Disorder Testing Market Competition:
Key players
- Siemens Healthcare GmbH
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- Atlas Medical GmbH
- Horiba Ltd.
- Hyphen Bio Med
- Precision Biologics Incorporated
- Pfizer Inc.
- Baxter
Bleeding Disorder Testing Market Recent Developments
- In March 2021, F. Hoffmann La Roche Ltd. introduced eight new configurations for Cobas Pro integrated solutions, to increase throughput and testing efficiency.
More Insights Available
Future Market Insights, in its new offering, presents an unbiased analysis of the Global automotive axle market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights based on Product Type (Reagents & Consumables and Instruments), Indication (Hemophilia A, Hemophilia B, Von Willebrand Disease, Idiopathic Thrombocytopenic Purpura and Others), (Hospitals & Clinics, Diagnostic Centers and Others), across seven major regions (North America, Latin America, Europe, South Asia & Pacific, East Asia and Middle East & Africa).
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
